The South Korean company claims that its Syracuse Bio Campus, a former Bristol Myers Squibb facility, has one of the largest U.S. conjugation capabilities for ADC production.
The collaboration aims to develop an automated, scalable manufacturing platform for gene-modified blood stem cell therapies for sickle cell disease and beta-thalassemia.
The partnership gives SK pharmteco access to Prozomix’s library of more than 6,000 native biocatalysts to support complex active pharmaceutical ingredient synthesis.
